UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer

Cancer research (Chicago, Ill.), 2014-04, Vol.74 (8), p.2316-2327

2014

Link zum Volltext

Verfügbarkeit prüfen

ΔNp63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis

Cancer research (Chicago, Ill.), 2014-01, Vol.74 (1), p.320-329

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 49: Modulating insulin receptor splicing as a potential therapeutic approach for rhabdomyosarcoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.49-49

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5825: Mechanisms of intrinsic and acquired resistance to antibodies targeting IGF-1R in pediatric sarcoma cell lines

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5825-5825

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2472: Mechanisms of resistance to IGFR-targeted therapy in pediatric sarcomas

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2472-2472

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 286: Preclinical study: HDAC inhibition combined with gemcitabine for the treatment of leiomyosarcoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.286-286

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-014: Targeting insulin receptor splicing as a therapeutic intervention for pediatric rhabdomyosarcoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-014-LB-014

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract B40: Autocrine and paracrine IL-6 and IL-8 drive osteosarcoma lung tropism and facilitate metastasis

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (5_Supplement), p.B40-B40

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract A45: Autocrine and paracrine IL-6 and IL-8 drive osteosarcoma metastasis

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (20_Supplement), p.A45-A45

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2775: Development and characterization of a MEK1 inhibitor (AZD6244) sensitive childhood astrocytoma cell line

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2775-2775

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 25: Targeting c-Myc in pediatric sarcoma xenografts with the BET bromodomain inhibitor, JQ1, disrupts angiogenesis

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.25-25

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-036: Elevated STAT3 expression in ovarian tumor ascites regulates invasion and metastasis: a promising therapeutic target

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-036-LB-036

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5083: Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective anti-angiogenic strategy

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.5083-5083

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2308: ΔNp63 promotes neuroblastoma by regulating tumor angiogenesis

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2308-2308

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2753: Targeting bromodomain and extra-terminal (BET) family member BRD4 for treatment of pediatric sarcomas

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2753-2753

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3277: Insulin-like growth factor-2 (IGF-2) circumvents the antiangiogenic activity of SCH717454, a human antibody that blocks ligand binding to the Type 1 insulin-like growth factor receptor (IGF-1R)

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3277-3277

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-28: Suppression of ovarian tumor growth and metastasis with a STAT3 inhibitor, HO-3867, in preclinical orthotopic models and ex vivo cultures of ovarian cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-28-LB-28

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1720: HO-3867, a selective inhibitor of stat3, suppress ovarian tumor growth and metastasis in human tissue culture and in an orthotopic mouse model

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1720-1720

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5291: A novel gain of function of deltaNp63 in tumor angiogenesis

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5291-5291

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2317: Direct anti-angiogenic activity of a small molecular STAT3 inhibitor LLL12

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2317-2317

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2481: Exploiting BRAF mutation for therapy of childhood low-grade astrocytoma

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2481-2481

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1039: HO-3867, is selectively cytotoxic to ovarian cancer cells through a dual mechanism of action involving the STAT3 and AKT pathways

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1039-1039

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer

ΔNp63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis

Abstract 49: Modulating insulin receptor splicing as a potential therapeutic approach for rhabdomyosarcoma

Abstract 5825: Mechanisms of intrinsic and acquired resistance to antibodies targeting IGF-1R in pediatric sarcoma cell lines

Abstract 2472: Mechanisms of resistance to IGFR-targeted therapy in pediatric sarcomas

Abstract 286: Preclinical study: HDAC inhibition combined with gemcitabine for the treatment of leiomyosarcoma

Abstract LB-014: Targeting insulin receptor splicing as a therapeutic intervention for pediatric rhabdomyosarcoma

Abstract B40: Autocrine and paracrine IL-6 and IL-8 drive osteosarcoma lung tropism and facilitate metastasis

Abstract A45: Autocrine and paracrine IL-6 and IL-8 drive osteosarcoma metastasis

Abstract 2775: Development and characterization of a MEK1 inhibitor (AZD6244) sensitive childhood astrocytoma cell line

Abstract 25: Targeting c-Myc in pediatric sarcoma xenografts with the BET bromodomain inhibitor, JQ1, disrupts angiogenesis

Abstract LB-036: Elevated STAT3 expression in ovarian tumor ascites regulates invasion and metastasis: a promising therapeutic target

Abstract 5083: Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective anti-angiogenic strategy

Abstract 2308: ΔNp63 promotes neuroblastoma by regulating tumor angiogenesis

Abstract 2753: Targeting bromodomain and extra-terminal (BET) family member BRD4 for treatment of pediatric sarcomas

Abstract 3277: Insulin-like growth factor-2 (IGF-2) circumvents the antiangiogenic activity of SCH717454, a human antibody that blocks ligand binding to the Type 1 insulin-like growth factor receptor (IGF-1R)

Abstract LB-28: Suppression of ovarian tumor growth and metastasis with a STAT3 inhibitor, HO-3867, in preclinical orthotopic models and ex vivo cultures of ovarian cancer

Abstract 1720: HO-3867, a selective inhibitor of stat3, suppress ovarian tumor growth and metastasis in human tissue culture and in an orthotopic mouse model

Abstract 5291: A novel gain of function of deltaNp63 in tumor angiogenesis

Abstract 2317: Direct anti-angiogenic activity of a small molecular STAT3 inhibitor LLL12

Abstract 2481: Exploiting BRAF mutation for therapy of childhood low-grade astrocytoma

Abstract 1039: HO-3867, is selectively cytotoxic to ovarian cancer cells through a dual mechanism of action involving the STAT3 and AKT pathways

Aktive Filter

Suchergebnisse filtern